RPRX
Royalty PharmaPlc
Royalty PharmaPlc historical holders
total: 4
Berkshire Hathaway Royalty PharmaPlc transactions over time
- Total transactions:
- 4
- New positions:
- 1
- Sold out:
- 1
- Reduced:
- 2
- Held since:
- 2021 Q3
- Held for:
- 3 quarters
- Latest activity:
- 2022 Q2
Warren Buffett has been an institutional investor in Royalty PharmaPlc (RPRX) since 2021 Q3. According to 2026 Q1 report, Warren Buffett doesn't hold any shares. The fund/company first acquired RPRX in 2021 Q3, initially purchasing about 13.15M shares. Since the initial investment, Berkshire Hathaway has made 3 more transactions in this position.
When did Warren Buffett exit their RPRX position?
Warren Buffett no longer holds Royalty PharmaPlc (RPRX). They sold off their entire position in 2022 Q2, closing out an investment that began in 2021 Q3.
When did Warren Buffett first invest in RPRX?
Warren Buffett first invested in Royalty PharmaPlc (RPRX) in 2021 Q3 at the reported quarter-end price of $36.14 per share, acquiring 13,145,902 shares in their initial purchase.
What is Warren Buffett's average cost basis for RPRX?
Based on historical transaction data, Warren Buffett's estimated cost basis for Royalty PharmaPlc (RPRX) is approximately $36.14 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $36.14
- Weighted AVG sell price:
- $39.26
RPRX transactions history by Berkshire Hathaway
4 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2022 Q2
|
0.00%
|
0
|
$38.96
|
|
-100% (-1,496,372)
|
-0.02%
|
|
2022 Q1
|
0.02%
|
1,496,372
|
$38.96
|
$58,299,000
|
-82.70% (-7,151,896)
|
-0.08%
|
|
2021 Q4
|
0.10%
|
8,648,268
|
$39.85
|
$344,633,000
|
-34.21% (-4,497,634)
|
-0.06%
|
|
2021 Q3
|
0.16%
|
13,145,902
|
$36.14
|
$475,093,000
|
new
|
+0.16%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.